Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142 Gastrointestinal Stromal Tumors 71 Leukemia 69 Leukemia, Myeloid, Chronic-Phase 50 Precursor Cell Lymphoblastic Leukemia-Lymphoma 43 Blast Crisis 22 Neoplasms 15 Brain Neoplasms 15 Philadelphia Chromosome 14 Melanoma 13 Sarcoma 12 Neoplasm Metastasis 12 Leukemia, Myeloid, Acute 12 Leukemia, Myeloid, Accelerated Phase 12 Glioblastoma 12 Lung Neoplasms 11 Prostatic Neoplasms 10 Leukemia, Myeloid 9 Gliosarcoma 9 Glioma 8 Breast Neoplasms 8 Primary Myelofibrosis 7 Leukemia, Myelomonocytic, Chronic 7 Central Nervous System Neoplasms 7 Astrocytoma 7 Recurrence 6 Polycythemia Vera 6 Ovarian Neoplasms 6 Oligodendroglioma 6 Myeloproliferative Disorders 6

Interventions

trametinib 1 dabrafenib 1 Surgical Procedures, Operative 1 Pharmaceutical Preparations 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Malignant Neoplasm × Imatinib Mesylate × Clear all

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡